
Opinion|Videos|June 21, 2024
AUA 2024: Outlining BOND-003 Data for NMIBC Therapy
Author(s)Gary Steinberg, MD, FACS
Expert urologist reviews the BOND-003 study, discussing its design, interim outcomes, safety and efficacy data, and the potential for cretostimogene grenadenorepvec to provide a durable response in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- Focusing on the BOND-003 study, please review the study design, key interim outcomes, and safety and efficacy data.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Sildenafil cream for female sexual arousal disorder available to prescribe in select states
2
Experts urge FDA to revisit labeling for testosterone replacement therapy in men
3
FDA approves ProVee System for benign prostatic hyperplasia
4
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
5



















